Reconsidering anion inhibitors in the general context of drug design studies of modulators of activity of the classical enzyme carbonic anhydrase

References

• Meldrum NU, Roughton FJ. Carbonic anhydrase. Its preparation and properties. J Physiol 1933;80:113–42.
   PubMedGoogle Scholar
• Maren TH. Carbonic anhydrase: chemistry, physiology, and inhibition. Physiol Rev 1967;47:595–781.
   PubMed Web of Science ®Google Scholar
• Lindskog S, Malmstrom BG. Metal binding and catalytic activity in bovine carbonic anhydrase. J Biol Chem 1962;237:1129–37.
   PubMed Web of Science ®Google Scholar
• Lindskog S, Coleman JE. The catalytic mechanism of carbonic anhydrase. Proc Natl Acad Sci USA 1973;70:2505–8.
   PubMed Web of Science ®Google Scholar
• Thorslund A, Lindskog S. Studies of the esterase activity and the anion inhibition of bovine zinc and cobalt carbonic anhydrases. Eur J Biochem 1967;3:117–23.
   PubMedGoogle Scholar
• Strandberg B, Tilander B, Fridborg K, et al. The crystallization and x-ray investigation of one form of human carbonic anhydrase. J Mol Biol 1962;5:583–4.
   PubMed Web of Science ®Google Scholar
• Liljas A, Kannan KK, Bergstén PC, et al. Crystal structure of human carbonic anhydrase C. Nat New Biol 1972;235:131–7.
   PubMedGoogle Scholar
• Keilin D, Mann T. Carbonic anhydrase. Purification and nature of the enzyme. Biochem J 1940;34:1163–76.
   PubMedGoogle Scholar
• Krebs HA. Inhibition of carbonic anhydrase by sulphonamides. Biochem J 1948;43:525–8.
   PubMed Web of Science ®Google Scholar
• Krebs HA, Roughton FJ. Carbonic anhydrase as a tool in studying the mechanism of reactions involving H(2)CO(3), CO(2) or HCO(3)'. Biochem J 1948;43:550–5.
   PubMed Web of Science ®Google Scholar
• Supuran CT. Carbonic anhydrases: novel therapeutic applications for inhibitors and activators. Nat Rev Drug Discov 2008;7:168–81.
   PubMed Web of Science ®Google Scholar
• Alterio V, Di Fiore A, D’Ambrosio K, et al. Multiple binding modes of inhibitors to carbonic anhydrases: how to design specific drugs targeting 15 different isoforms? Chem Rev 2012;112:4421–68.
   PubMed Web of Science ®Google Scholar
• Krishnamurthy VM, Kaufman GK, Urbach AR, et al. Carbonic anhydrase as a model for biophysical and physical-organic studies of proteins and protein-ligand binding. Chem Rev 2008;108:946–1051.
   PubMed Web of Science ®Google Scholar
• Mishra CB, Tiwari M, Supuran CT. Progress in the development of human carbonic anhydrase inhibitors and their pharmacological applications: where are we today? Med Res Rev 2020;40:2485–565.
   PubMed Web of Science ®Google Scholar
• Neri D, Supuran CT. Interfering with pH regulation in tumours as a therapeutic strategy. Nat Rev Drug Discov 2011;10:767–77.
   PubMed Web of Science ®Google Scholar
• (a) Supuran CT. Structure and function of carbonic anhydrases. Biochem J 2016;473:2023–32.
   PubMed Web of Science ®Google Scholar
  (b) Supuran CT. Carbonic anhydrases and metabolism. Metabolites 2018;8:25.
   PubMed Web of Science ®Google Scholar
• (a) Capasso C, Supuran CT. An overview of the alpha-, beta- and gamma-carbonic anhydrases from Bacteria: can bacterial carbonic anhydrases shed new light on evolution of bacteria? J Enzyme Inhib Med Chem 2015;30:325–32.
   PubMed Web of Science ®Google Scholar
  (b) Ozensoy Guler O, Capasso C, Supuran CT. A magnificent enzyme superfamily: carbonic anhydrases, their purification and characterization. J Enzyme Inhib Med Chem 2016;31:689–94. (c) Bertucci A, Moya A, Tambutté S, et al. Carbonic anhydrases in anthozoan corals-a review. Bioorg Med Chem 2013;21:1437–50.
   PubMed Web of Science ®Google Scholar
• (a) Kikutani S, Nakajima K, Nagasato C, et al. Thylakoid luminal theta-carbonic anhydrase critical for growth and photosynthesis in the marine diatom Phaeodactylum tricornutum. Proc Natl Acad Sci USA 2016;113:9828–33.
   PubMed Web of Science ®Google Scholar
  (b) Jin S, Vullo D, Bua S, et al. Structural and biochemical characterization of novel carbonic anhydrases from Phaeodactylum tricornutum. Acta Crystallogr D Struct Biol 2020;76:676–86. (c) Del Prete S, Bua S, Supuran CT, Capasso C. Escherichia coli γ-carbonic anhydrase: characterisation and effects of simple aromatic/heterocyclic sulphonamide inhibitors. J Enzyme Inhib Med Chem 2020;35:1545–54. (d) Kaur J, Cao X, Abutaleb NS, et al. Optimization of acetazolamide-based scaffold as potent inhibitors of vancomycin-resistant enterococcus. J Med Chem 2020;63:9540–62.
   PubMedGoogle Scholar
• (a) Xu Y, Feng L, Jeffrey PD, et al. Structure and metal exchange in the cadmium carbonic anhydrase of marine diatoms. Nature 2008;452:56–61.
   PubMed Web of Science ®Google Scholar
  (b) Cox EH, McLendon GL, Morel FM, et al. The active site structure of Thalassiosira weissflogii carbonic anhydrase 1. Biochemistry 2000;39:12128–30. (c) Alterio V, Langella E, Viparelli F, et al. Structural and inhibition insights into carbonic anhydrase CDCA1 from the marine diatom Thalassiosira weissflogii. Biochimie 2012;94:1232–41.
   PubMed Web of Science ®Google Scholar
• (a) Capasso C, Supuran CT. Bacterial, fungal and protozoan carbonic anhydrases as drug targets. Expert Opin Ther Targets 2015;19:1689–704.
   PubMed Web of Science ®Google Scholar
  (b) Supuran CT, Capasso C. The eta-class carbonic anhydrases as drug targets for antimalarial agents. Expert Opin Ther Targets 2015;19:551–63. (c) Supuran CT, Capasso C. Antibacterial carbonic anhydrase inhibitors: an update on the recent literature. Expert Opin Ther Pat 2020;30:963–82. (d) Angeli A, Pinteala M, Maier SS, et al. Inhibition of α-, β-, γ-, δ-, ζ- and η-class carbonic anhydrases from bacteria, fungi, algae, diatoms and protozoans with famotidine. J Enzyme Inhib Med Chem 2019;34:644–50.
   PubMed Web of Science ®Google Scholar
• (a) Jensen EL, Clement R, Kosta A, et al. A new widespread subclass of carbonic anhydrase in marine phytoplankton. Isme J 2019;13:2094–106.
   PubMed Web of Science ®Google Scholar
  (b) Del Prete S, Nocentini A, Supuran CT, Capasso C. Bacterial ι-carbonic anhydrase: a new active class of carbonic anhydrase identified in the genome of the Gram-negative bacterium Burkholderia territorii. J Enzyme Inhib Med Chem 2020;35:1060–8. (c) Petreni A, De Luca V, Scaloni A, et al. Anion inhibition studies of the Zn(II)-bound ι-carbonic anhydrase from the Gram-negative bacterium Burkholderia territorii. J Enzyme Inhib Med Chem 2021;36:372–6. (d) De Luca V, Petreni A, Nocentini A, et al. Effect of sulfonamides and their structurally related derivatives on the activity of ι -carbonic anhydrase from Burkholderia territorii. Int J Mol Sci 2021;22:571.
   PubMed Web of Science ®Google Scholar
• (a) Tripp BC, Bell CB, 3rd, Cruz F, et al. A role for iron in an ancient carbonic anhydrase. J Biol Chem 2004;279:6683–7.
   PubMed Web of Science ®Google Scholar
  (b) Zimmerman SA, Ferry JG, Supuran CT. Inhibition of the archaeal beta-class (Cab) and gamma-class (Cam) carbonic anhydrases. Curr Top Med Chem 2007;7:901–8.
   PubMed Web of Science ®Google Scholar
• (a) Del Prete S, Vullo D, Fisher GM, et al. Discovery of a new family of carbonic anhydrases in the malaria pathogen Plasmodium falciparum-the η-carbonic anhydrases. Bioorg Med Chem Lett 2014;24:4389–96.
   PubMed Web of Science ®Google Scholar
  (b) De Simone G, Di Fiore A, Capasso C, Supuran CT. The zinc coordination pattern in the η-carbonic anhydrase from Plasmodium falciparum is different from all other carbonic anhydrase genetic families. Bioorg Med Chem Lett 2015;25:1385–9.
   PubMed Web of Science ®Google Scholar
• (a) Domsic JF, Avvaru BS, Kim CU, et al. Entrapment of carbon dioxide in the active site of carbonic anhydrase II. J Biol Chem 2008;283:30766–71.
   PubMed Web of Science ®Google Scholar
  (b) Sjöblom B, Polentarutti M, Djinovic-Carugo K. Structural study of X-ray induced activation of carbonic anhydrase. Proc Natl Acad Sci USA 2009;106:10609–13.
   PubMed Web of Science ®Google Scholar
• Aggarwal M, Chua TK, Pinard MA, et al. Carbon dioxide "trapped" in a β-carbonic anhydrase. Biochemistry 2015;54:6631–8.
   PubMed Web of Science ®Google Scholar
• De Simone G, Supuran CT. (In)organic anions as carbonic anhydrase inhibitors. J Inorg Biochem 2012;111:117–29.
   PubMed Web of Science ®Google Scholar
• (a) Bertini I, Luchinat C, Scozzafava A. Binding affinity of bicarboxylate ions for cobalt (II) bovine carbonic anhydrase. Bioinorg Chem 1978;9:93–100.
   PubMedGoogle Scholar
  (b) Bertini I, Luchinat C, Scozzafava A. Interaction of cobalt-bovine carbonic anhydrase with the acetate ion. Biochim Biophys Acta 1976;452:239–44.
   PubMedGoogle Scholar
• (a) Bertini I, Luchinat C, Pierattelli R, Vila AJ. The interaction of acetate and formate with cobalt carbonic anhydrase. An NMR study. Eur J Biochem 1992;208:607–15.
   PubMedGoogle Scholar
  (b) Bertini I, Luchinat C, Scozzafava A. A 31P NMR study of phosphate in presence of cobalt(II)- and copper(II)- substituted bovine carbonic anhydrase B. FEBS Lett 1978;93:251–4.
   PubMed Web of Science ®Google Scholar
• (a) Taylor JS, Coleman JE. Electron spin resonance of 63Cu and 65Cu carbonic anhydrases. Resolution of nitrogen ligand superhyperfine structure. J Biol Chem 1973;248:749–55.
   PubMed Web of Science ®Google Scholar
  (b) Coleman JE, Coleman RV. Magnetic circular dichroism of Co (II) carbonic anhydrase. J Biol Chem 1972;247:4718–28.
   PubMed Web of Science ®Google Scholar
• Coleman JE. Mechanism of action of carbonic anhydrase. Substrate, sulfonamide, and anion binding. J Biol Chem 1967;242:5212–9.
   PubMed Web of Science ®Google Scholar
• West D, Pinard MA, Tu C, et al. Human carbonic anhydrase II-cyanate inhibitor complex: putting the debate to rest. Acta Crystallogr F Struct Biol Commun 2014;70:1324–7.
   PubMed Web of Science ®Google Scholar
• Jönsson BM, Håkansson K, Liljas A. The structure of human carbonic anhydrase II in complex with bromide and azide. FEBS Lett 1993;322:186–90.
   PubMed Web of Science ®Google Scholar
• Ferraroni M, Gaspari R, Scozzafava A, et al. Dioxygen, an unexpected carbonic anhydrase ligand. J Enzyme Inhib Med Chem 2018;33:999–1005.
   PubMed Web of Science ®Google Scholar
• Lindahl M, Svensson LA, Liljas A. Metal poison inhibition of carbonic anhydrase. Proteins 1993;15:177–82.
   PubMed Web of Science ®Google Scholar
• Peng Z, Merz KM, Jr, Banci L. Binding of cyanide, cyanate, and thiocyanate to human carbonic anhydrase II. Proteins 1993;17:203–16.
   PubMed Web of Science ®Google Scholar
• Supuran CT, Conroy CW, Maren TH. Is cyanate a carbonic anhydrase substrate? Proteins 1997;27:272–8.
   PubMed Web of Science ®Google Scholar
• Maren TH. Kinetics, equilibrium and inhibition in the Hansson histochemical procedure for carbonic anhydrase: a validation of the method. Histochem J 1980;12:183–90.
   PubMedGoogle Scholar
• Maren TH. Inhibition by anions of human red cell carbonic anhydrase B: physiological and biochemical implications. Science 1976;194:746–7.
   PubMedGoogle Scholar
• Briganti F, Mangani S, Scozzafava A, et al. Carbonic anhydrase catalyzes cyanamide hydration to urea: is it mimicking the physiological reaction? J Biol Inorg Chem 1999;4:528–36.
   PubMed Web of Science ®Google Scholar
• Temperini C, Scozzafava A, Supuran CT. Carbonic anhydrase inhibitors. X-ray crystal studies of the carbonic anhydrase II-trithiocarbonate adduct-an inhibitor mimicking the sulfonamide and urea binding to the enzyme. Bioorg Med Chem Lett 2010;20:474–8.
   PubMed Web of Science ®Google Scholar
• Guerri A, Briganti F, Scozzafava A, et al. Mechanism of cyanamide hydration catalyzed by carbonic anhydrase II suggested by cryogenic X-ray diffraction. Biochemistry 2000;39:12391–7.
   PubMed Web of Science ®Google Scholar
• Nettles WL, Song H, Farquhar ER, et al. Characterization of the Copper(II) Binding Sites in Human Carbonic Anhydrase II. Inorg Chem 2015;54:5671–80.
   PubMed Web of Science ®Google Scholar
• Andring JT, Kim CU, McKenna R. Structure and mechanism of copper-carbonic anhydrase II: a nitrite reductase. IUCrJ 2020;7:287–93.
   PubMed Web of Science ®Google Scholar
• Carta F, Scozzafava A, Supuran CT. Sulfonamides: a patent review (2008–2012). Expert Opin Ther Pat 2012;22:747–58.
   PubMed Web of Science ®Google Scholar
• Supuran CT. Carbon- versus sulphur-based zinc binding groups for carbonic anhydrase inhibitors? J Enzyme Inhib Med Chem 2018;33:485–95.
   PubMed Web of Science ®Google Scholar
• Scozzafava A, Carta F, Supuran CT. Secondary and tertiary sulfonamides: a patent review (2008–2012). Expert Opin Ther Pat 2013;23:203–13.
   PubMed Web of Science ®Google Scholar
• Eriksson AE, Kylsten PM, Jones TA, Liljas A. Crystallographic studies of inhibitor binding sites in human carbonic anhydrase II: a pentacoordinated binding of the SCN- ion to the zinc at high pH. Proteins 1988;4:283–93.
   PubMed Web of Science ®Google Scholar
• Supuran CT. Exploring the multiple binding modes of inhibitors to carbonic anhydrases for novel drug discovery. Expert Opin Drug Discov 2020;15:671–86.
   PubMed Web of Science ®Google Scholar
• Supuran CT. Carbonic anhydrase inhibition and the management of hypoxic tumors. Metabolites 2017;7:48.
   PubMed Web of Science ®Google Scholar
• Supuran CT. Advances in structure-based drug discovery of carbonic anhydrase inhibitors. Expert Opin Drug Discov 2017;12:61–88.
   PubMed Web of Science ®Google Scholar
• Carta F, Supuran CT. Diuretics with carbonic anhydrase inhibitory action: a patent and literature review (2005–2013). Expert Opin Ther Pat 2013;23:681–91.
   PubMed Web of Science ®Google Scholar
• Nocentini A, Supuran CT. Advances in the structural annotation of human carbonic anhydrases and impact on future drug discovery. Expert Opin Drug Discov 2019;14:1175–97.
   PubMed Web of Science ®Google Scholar
• Supuran CT. Carbonic anhydrase inhibitors and their potential in a range of therapeutic areas. Expert Opin Ther Pat 2018;28:709–12.
   PubMed Web of Science ®Google Scholar
• Scozzafava A, Supuran CT, Carta F. Antiobesity carbonic anhydrase inhibitors: a literature and patent review. Expert Opin Ther Pat 2013;23:725–35.
   PubMed Web of Science ®Google Scholar
• Supuran CT. Applications of carbonic anhydrases inhibitors in renal and central nervous system diseases. Expert Opin Ther Pat 2018;28:713–21.
   PubMed Web of Science ®Google Scholar
• Supuran CT, Altamimi ASA, Carta F. Carbonic anhydrase inhibition and the management of glaucoma: a literature and patent review 2013-2019. Expert Opin Ther Pat 2019;29:781–92.
   PubMed Web of Science ®Google Scholar
• Supuran CT. The management of glaucoma and macular degeneration. Expert Opin Ther Pat 2019;29:745–7.
   PubMed Web of Science ®Google Scholar
• Wistrand PJ. Carbonic anhydrase research: a clinical perspective, past and future. EXS 2000;90:597–609.
   Google Scholar
• Maren TH. Sulfonamides and secretion of aqueous humor. J Exp Zool 1997;279:490–7.
   PubMedGoogle Scholar
• Supuran CT, Nicolae A, Popescu A. Carbonic anhydrase inhibitors. Part 35. Synthesis of Schiff bases derived from sulfanilamide and aromatic aldehydes: the first inhibitors with equally high affinity towards cytosolic and membrane-bound isozymes. Eur J Med Chem 1996;31:431–8.
   Web of Science ®Google Scholar
• Scozzafava A, Menabuoni L, Mincione F, et al. Carbonic anhydrase inhibitors. Synthesis of water-soluble, topically effective, intraocular pressure-lowering aromatic/heterocyclic sulfonamides containing cationic or anionic moieties: is the tail more important than the ring? J Med Chem 1999;42:2641–50.
   PubMed Web of Science ®Google Scholar
• D'Ascenzio M, Secci D, Carradori S, et al. 1,3-Dipolar Cycloaddition, HPLC Enantioseparation, and Docking Studies of Saccharin/Isoxazole and Saccharin/Isoxazoline Derivatives as Selective Carbonic Anhydrase IX and XII Inhibitors. J Med Chem 2020;63:2470–88.
   PubMed Web of Science ®Google Scholar
• Güzel O, Temperini C, Innocenti A, et al. Carbonic anhydrase inhibitors. Interaction of 2-(hydrazinocarbonyl)-3-phenyl-1H-indole-5-sulfonamide with 12 mammalian isoforms: kinetic and X-ray crystallographic studies. Bioorg Med Chem Lett 2008;18:152–8.
   PubMed Web of Science ®Google Scholar
• Biswas S, Aggarwal M, Güzel Ö, et al. Conformational variability of different sulfonamide inhibitors with thienyl-acetamido moieties attributes to differential binding in the active site of cytosolic human carbonic anhydrase isoforms. Bioorg Med Chem 2011;19:3732–8.
   PubMed Web of Science ®Google Scholar
• Wagner J, Avvaru BS, Robbins AH, et al. Coumarinyl-substituted sulfonamides strongly inhibit several human carbonic anhydrase isoforms: solution and crystallographic investigations. Bioorg Med Chem 2010;18:4873–8.
   PubMed Web of Science ®Google Scholar
• Avvaru BS, Wagner JM, Maresca A, et al. Carbonic anhydrase inhibitors. The X-ray crystal structure of human isoform II in adduct with an adamantyl analogue of acetazolamide resides in a less utilized binding pocket than most hydrophobic inhibitors. Bioorg Med Chem Lett 2010;20:4376–81.
   PubMed Web of Science ®Google Scholar
• Carta F, Garaj V, Maresca A, et al. Sulfonamides incorporating 1,3,5-triazine moieties selectively and potently inhibit carbonic anhydrase transmembrane isoforms IX, XII and XIV over cytosolic isoforms I and II: solution and X-ray crystallographic studies. Bioorg Med Chem 2011;19:3105–19.
   PubMed Web of Science ®Google Scholar
• Carta F, Birkmann A, Pfaff T, et al. Lead development of thiazolylsulfonamides with carbonic anhydrase inhibitory action. J Med Chem 2017;60:3154–64.
   PubMed Web of Science ®Google Scholar
• Alterio V, Vitale RM, Monti SM, et al. Carbonic anhydrase inhibitors: X-ray and molecular modeling study for the interaction of a fluorescent antitumor sulfonamide with isozyme II and IX. J Am Chem Soc 2006;128:8329–35.
   PubMed Web of Science ®Google Scholar
• Pacchiano F, Aggarwal M, Avvaru BS, et al. Selective hydrophobic pocket binding observed within the carbonic anhydrase II active site accommodate different 4-substituted-ureido-benzenesulfonamides and correlate to inhibitor potency. Chem Commun (Camb) 2010;46:8371–3.
   PubMed Web of Science ®Google Scholar
• Mboge MY, Mahon BP, Lamas N, et al. Structure activity study of carbonic anhydrase IX: selective inhibition with ureido-substituted benzenesulfonamides. Eur J Med Chem 2017;132:184–91.
   PubMed Web of Science ®Google Scholar
• Pacchiano F, Carta F, McDonald PC, et al. Ureido-substituted benzenesulfonamides potently inhibit carbonic anhydrase IX and show antimetastatic activity in a model of breast cancer metastasis. J Med Chem 2011;54:1896–902.
   PubMed Web of Science ®Google Scholar
• Tanpure RP, Ren B, Peat TS, et al. Carbonic anhydrase inhibitors with dual-tail moieties to match the hydrophobic and hydrophilic halves of the carbonic anhydrase active site. J Med Chem 2015;58:1494–501.
   PubMed Web of Science ®Google Scholar
• Bonardi A, Nocentini A, Bua S, et al. Sulfonamide inhibitors of human carbonic anhydrases designed through a three-tails approach: improving ligand/isoform matching and selectivity of action. J Med Chem 2020;63:7422–44.
   PubMed Web of Science ®Google Scholar
• Gieling RG, Babur M, Mamnani L, et al. Antimetastatic effect of sulfamate carbonic anhydrase IX inhibitors in breast carcinoma xenografts. J Med Chem 2012;55:5591–600.
   PubMed Web of Science ®Google Scholar
• Bozdag M, Carta F, Ceruso M, et al. Discovery of 4-hydroxy-3-(3-(phenylureido)benzenesulfonamides as SLC-0111 analogues for the treatment of hypoxic tumors overexpressing carbonic anhydrase IX. J Med Chem 2018;61:6328–38.
   PubMed Web of Science ®Google Scholar
• Akocak S, Lolak N, Bua S, et al. Synthesis and biological evaluation of novel N,N'-diaryl cyanoguanidines acting as potent and selective carbonic anhydrase II inhibitors . Bioorg Chem 2018;77:245–51.
   PubMed Web of Science ®Google Scholar
• Lolak N, Akocak S, Bua S, et al. Design and synthesis of novel 1,3-diaryltriazene-substituted sulfonamides as potent and selective carbonic anhydrase II inhibitors. Bioorg Chem 2018;77:542–7.
   PubMed Web of Science ®Google Scholar
• Lomelino CL, Mahon BP, Carta F, et al. Kinetic and X-ray crystallographic investigations on carbonic anhydrase isoforms I, II, IX and XII of a thioureido analog of SLC-0111. Bioorg Med Chem 2016;24:976–81.
   PubMed Web of Science ®Google Scholar
• Angeli A, Tanini D, Peat TS, et al. Discovery of new selenoureido analogues of 4-(4-Fluorophenylureido)benzenesulfonamide as Carbonic Anhydrase Inhibitors. ACS Med Chem Lett 2017;8:963–8.
   PubMed Web of Science ®Google Scholar
• Eldehna WM, Abo-Ashour MF, Berrino E, et al. SLC-0111 enaminone analogs, 3/4-(3-aryl-3-oxopropenyl) aminobenzenesulfonamides, as novel selective subnanomolar inhibitors of the tumor-associated carbonic anhydrase isoform IX. Bioorg Chem 2019;83:549–58.
   PubMed Web of Science ®Google Scholar
• Congiu C, Onnis V, Deplano A, et al. Synthesis of sulfonamides incorporating piperazinyl-ureido moieties and their carbonic anhydrase I, II, IX and XII inhibitory activity. Bioorg Med Chem Lett 2015;25:3850–3.
   PubMed Web of Science ®Google Scholar
• Moi D, Nocentini A, Deplano A, et al. Appliance of the piperidinyl-hydrazidoureido linker to benzenesulfonamide compounds: synthesis, in vitro and in silico evaluation of potent carbonic anhydrase II, IX and XII inhibitors. Bioorg Chem 2020;98:103728.
   PubMed Web of Science ®Google Scholar
• Abo-Ashour MF, Eldehna WM, Nocentini A, et al. Novel synthesized SLC-0111 thiazole and thiadiazole analogues: determination of their carbonic anhydrase inhibitory activity and molecular modeling studies. Bioorg Chem 2019;87:794–802.
   PubMed Web of Science ®Google Scholar
• Alkhaldi AAM, Al-Sanea MM, Nocentini A, et al. 3-Methylthiazolo[3,2-a]benzimidazole-benzenesulfonamide conjugates as novel carbonic anhydrase inhibitors endowed with anticancer activity: design, synthesis, biological and molecular modeling studies. Eur J Med Chem 2020;207:112745.
   PubMed Web of Science ®Google Scholar
• Iikuni S, Ono M, Watanabe H, et al. Cancer radiotheranostics targeting carbonic anhydrase-IX with 111In- and 90Y-labeled ureidosulfonamide scaffold for SPECT imaging and radionuclide-based therapy. Theranostics 2018;8:2992–3006.
   PubMed Web of Science ®Google Scholar
• Eldehna WM, Fares M, Ceruso M, et al. Amido/ureidosubstituted benzenesulfonamides-isatin conjugates as low nanomolar/subnanomolar inhibitors of the tumor-associated carbonic anhydrase isoform XII. Eur J Med Chem 2016;110:259–66.
   PubMed Web of Science ®Google Scholar
• Eldehna WM, Abo-Ashour MF, Nocentini A, et al. Enhancement of the tail hydrophobic interactions within the carbonic anhydrase IX active site via structural extension: design and synthesis of novel N-substituted isatins-SLC-0111 hybrids as carbonic anhydrase inhibitors and antitumor agents. Eur J Med Chem 2019;162:147–60.
   PubMed Web of Science ®Google Scholar
• Carta F, Vullo D, Osman SM, et al. Synthesis and carbonic anhydrase inhibition of a series of SLC-0111 analogs. Bioorg Med Chem 2017;25:2569–76.
   PubMed Web of Science ®Google Scholar
• Akgul O, Singh S, Andring JT, et al. Handling drug-target selectivity: a study on ureido containing Carbonic Anhydrase inhibitors. Eur J Med Chem 2020;113035.DOI:https://doi.org/10.1016/j.ejmech.2020.113035
   Google Scholar
• Nocentini A, Gratteri P, Supuran CT. Phosphorus versus sulfur: discovery of benzenephosphonamidates as versatile sulfonamide-mimic chemotypes acting as carbonic anhydrase inhibitors. Chemistry 2019;25:1188–92.
   PubMed Web of Science ®Google Scholar
• Carta F, Aggarwal M, Maresca A, et al. Dithiocarbamates: a new class of carbonic anhydrase inhibitors. Crystallographic and kinetic investigations. Chem Commun (Camb) 2012;48:1868–70.
   PubMed Web of Science ®Google Scholar
• Vullo D, Durante M, Di Leva FS, et al. Monothiocarbamates strongly inhibit carbonic anhydrases in vitro and possess intraocular pressure lowering activity in an animal model of glaucoma. J Med Chem 2016;59:5857–67.
   PubMed Web of Science ®Google Scholar
• Carta F, Akdemir A, Scozzafava A, et al. Xanthates and trithiocarbonates strongly inhibit carbonic anhydrases and show antiglaucoma effects in vivo. J Med Chem 2013;56:4691–700.
   PubMed Web of Science ®Google Scholar
• Angeli A, Tanini D, Nocentini A, et al. Selenols: a new class of carbonic anhydrase inhibitors. Chem Commun (Camb) 2019;55:648–51.
   PubMed Web of Science ®Google Scholar
• Tanini D, Capperucci A, Ferraroni M, et al. Direct and straightforward access to substituted alkyl selenols as novel carbonic anhydrase inhibitors. Eur J Med Chem 2020;185:111811.
   PubMed Web of Science ®Google Scholar
• Langella E, D'Ambrosio K, D'Ascenzio M, et al. A Combined crystallographic and theoretical study explains the capability of carboxylic acids to adopt multiple binding modes in the active site of carbonic anhydrases. Chemistry 2016;22:97–100.
   PubMed Web of Science ®Google Scholar
• Di Fiore A, Maresca A, Supuran CT, et al. Hydroxamate represents a versatile zinc binding group for the development of new carbonic anhydrase inhibitors. Chem Commun (Camb) 2012;48:8838–40.
   PubMed Web of Science ®Google Scholar
• Alterio V, Cadoni R, Esposito D, et al. Benzoxaborole as a new chemotype for carbonic anhydrase inhibition. Chem Commun (Camb) 2016;52:11983–6.
   PubMed Web of Science ®Google Scholar
• Langella E, Alterio V, D'Ambrosio K, et al. Exploring benzoxaborole derivatives as carbonic anhydrase inhibitors: a structural and computational analysis reveals their conformational variability as a tool to increase enzyme selectivity. J Enzyme Inhib Med Chem 2019;34:1498–505.
   PubMed Web of Science ®Google Scholar
• Nocentini A, Supuran CT, Winum JY. Benzoxaborole compounds for therapeutic uses: a patent review (2010–2018). Expert Opin Ther Pat 2018;28:493–504.
   PubMed Web of Science ®Google Scholar
• De Simone G, Angeli A, Bozdag M, et al. Inhibition of carbonic anhydrases by a substrate analog: benzyl carbamate directly coordinates the catalytic zinc ion mimicking bicarbonate binding. Chem Commun (Camb) 2018;54:10312–5.
   PubMed Web of Science ®Google Scholar
• Carta F, Temperini C, Innocenti A, et al. Polyamines inhibit carbonic anhydrases by anchoring to the zinc-coordinated water molecule. J Med Chem 2010;53:5511–22.
   PubMed Web of Science ®Google Scholar
• Nair SK, Ludwig PA, Christianson DW. Two-site binding of phenol in the active site of human carbonic anhydrase II: structural implications for substrate association. J Am Chem Soc 1994;116:3659–60.
   Web of Science ®Google Scholar
• Innocenti A, Vullo D, Scozzafava A, et al. Carbonic anhydrase inhibitors: interactions of phenols with the 12 catalytically active mammalian isoforms (CA I-XIV). Bioorg Med Chem Lett 2008;18:1583–7.
   PubMed Web of Science ®Google Scholar
• Innocenti A, Vullo D, Scozzafava A, et al. Carbonic anhydrase inhibitors: inhibition of mammalian isoforms I-XIV with a series of substituted phenols including paracetamol and salicylic acid. Bioorg Med Chem 2008;16:7424–8.
   PubMed Web of Science ®Google Scholar
• (a) Bayram E, Senturk M, Kufrevioglu OI, et al. In vitro inhibition of salicylic acid derivatives on human cytosolic carbonic anhydrase isozymes I and II. Bioorg Med Chem 2008;16:9101–5.
   PubMed Web of Science ®Google Scholar
  (b) Innocenti A, Gülçin I, Scozzafava A, Supuran CT. Carbonic anhydrase inhibitors. Antioxidant polyphenols effectively inhibit mammalian isoforms I-XV. Bioorg Med Chem Lett 2010;20:5050–3.
   PubMed Web of Science ®Google Scholar
• Nocentini A, Bonardi A, Gratteri P, et al. Steroids interfere with human carbonic anhydrase activity by using alternative binding mechanisms. J Enzyme Inhib Med Chem 2018;33:1453–9.
   PubMed Web of Science ®Google Scholar
• Karioti A, Carta F, Supuran CT. Phenols and polyphenols as carbonic anhydrase inhibitors. Molecules 2016;21:1649.
   PubMed Web of Science ®Google Scholar
• Tars K, Vullo D, Kazaks A, et al. Sulfocoumarins (1,2-benzoxathiine-2,2-dioxides): a class of potent and isoform-selective inhibitors of tumor-associated carbonic anhydrases. J Med Chem 2013;56:293–300.
   PubMed Web of Science ®Google Scholar
• Grandane A, Tanc M, Žalubovskis R, Supuran CT. Synthesis of 6-aryl-substituted sulfocoumarins and investigation of their carbonic anhydrase inhibitory action. Bioorg Med Chem 2015;23:1430–6.
   PubMed Web of Science ®Google Scholar
• Pustenko A, Stepanovs D, Žalubovskis R, et al. 3H-1,2-benzoxathiepine 2,2-dioxides: a new class of isoform-selective carbonic anhydrase inhibitors. J Enzyme Inhib Med Chem 2017;32:767–75.
   PubMed Web of Science ®Google Scholar
• Grandane A, Nocentini A, Werner T, et al. Benzoxepinones: a new isoform-selective class of tumor associated carbonic anhydrase inhibitors. Bioorg Med Chem 2020;28:115496.
   PubMed Web of Science ®Google Scholar
• Ferraroni M, Carta F, Scozzafava A, et al. Thioxocoumarins show an alternative carbonic anhydrase inhibition mechanism compared to coumarins. J Med Chem 2016;59:462–73.
   PubMed Web of Science ®Google Scholar
• Maresca A, Temperini C, Vu H, et al. Non-zinc mediated inhibition of carbonic anhydrases: coumarins are a new class of suicide inhibitors. J Am Chem Soc 2009;131:3057–62.
   PubMed Web of Science ®Google Scholar
• Maresca A, Temperini C, Pochet L, et al. Deciphering the mechanism of carbonic anhydrase inhibition with coumarins and thiocoumarins. J Med Chem 2010;53:335–44.
   PubMed Web of Science ®Google Scholar
• Temperini C, Innocenti A, Scozzafava A, et al. The coumarin-binding site in carbonic anhydrase accommodates structurally diverse inhibitors: the antiepileptic lacosamide as an example and lead molecule for novel classes of carbonic anhydrase inhibitors. J Med Chem 2010;53:850–4.
   PubMed Web of Science ®Google Scholar
• Supuran CT. Coumarin carbonic anhydrase inhibitors from natural sources. J Enzyme Inhib Med Chem 2020;35:1462–70.
   PubMed Web of Science ®Google Scholar
• Touisni N, Maresca A, McDonald PC, et al. Glycosyl coumarin carbonic anhydrase IX and XII inhibitors strongly attenuate the growth of primary breast tumors. J Med Chem 2011;54:8271–7.
   PubMed Web of Science ®Google Scholar
• Davis RA, Vullo D, Maresca A, et al. Natural product coumarins that inhibit human carbonic anhydrases. Bioorg Med Chem 2013;21:1539–43.
   PubMed Web of Science ®Google Scholar
• De Luca L, Mancuso F, Ferro S, et al. Inhibitory effects and structural insights for a novel series of coumarin-based compounds that selectively target human CA IX and CA XII carbonic anhydrases. Eur J Med Chem 2018;143:276–82.
   PubMed Web of Science ®Google Scholar
• Maresca A, Scozzafava A, Supuran CT. 7,8-disubstituted- but not 6,7-disubstituted coumarins selectively inhibit the transmembrane, tumor-associated carbonic anhydrase isoforms IX and XII over the cytosolic ones I and II in the low nanomolar/subnanomolar range. Bioorg Med Chem Lett 2010;20:7255–8.
   PubMed Web of Science ®Google Scholar
• Maresca A, Supuran CT. Coumarins incorporating hydroxy- and chloro-moieties selectively inhibit the transmembrane, tumor-associated carbonic anhydrase isoforms IX and XII over the cytosolic ones I and II. Bioorg Med Chem Lett 2010;20:4511–4.
   PubMed Web of Science ®Google Scholar
• Bonneau A, Maresca A, Winum JY, Supuran CT. Metronidazole-coumarin conjugates and 3-cyano-7-hydroxy-coumarin act as isoform-selective carbonic anhydrase inhibitors. J Enzyme Inhib Med Chem 2013;28:397–401.
   PubMed Web of Science ®Google Scholar
• D'Ambrosio K, Carradori S, Monti SM, et al. Out of the active site binding pocket for carbonic anhydrase inhibitors. Chem Commun (Camb) 2015;51:302–5.
   PubMed Web of Science ®Google Scholar
• Bouzina A, Berredjem M, Nocentini A, et al. Ninhydrins inhibit carbonic anhydrases directly binding to the metal ion. Eur J Med Chem 2021;209:112875.
   PubMed Web of Science ®Google Scholar
• D'Ambrosio K, Carradori S, Cesa S, et al. Catechols: a new class of carbonic anhydrase inhibitors. Chem Commun (Camb) 2020;56:13033–6.
   PubMed Web of Science ®Google Scholar
• (a) Supuran CT. How many carbonic anhydrase inhibition mechanisms exist? J Enzyme Inhib Med Chem 2016;31:345–60.
   PubMed Web of Science ®Google Scholar
  (b) Supuran CT. Structure-based drug discovery of carbonic anhydrase inhibitors. J Enzyme Inhib Med Chem 2012;27:759–72.
   PubMed Web of Science ®Google Scholar
• (a) Aggarwal M, Kondeti B, McKenna R. Anticonvulsant/antiepileptic carbonic anhydrase inhibitors: a patent review. Expert Opin Ther Pat 2013;23:717–24.
   PubMed Web of Science ®Google Scholar
  (b) Thiry A, Dogné JM, Supuran CT, Masereel B. Anticonvulsant sulfonamides/sulfamates/sulfamides with carbonic anhydrase inhibitory activity: drug design and mechanism of action. Curr Pharm Des 2008;14:661–71.
   PubMed Web of Science ®Google Scholar
• (a) Hen N, Bialer M, Yagen B, et al. Anticonvulsant 4-aminobenzenesulfonamide derivatives with branched-alkylamide moieties: X-ray crystallography and inhibition studies of human carbonic anhydrase isoforms I, II, VII, and XIV. J Med Chem 2011;54:3977–81.
   PubMed Web of Science ®Google Scholar
  (b) Thiry A, Dogné JM, Supuran CT, Masereel B. Carbonic anhydrase inhibitors as anticonvulsant agents. Curr Top Med Chem 2007;7:855–64.
   PubMed Web of Science ®Google Scholar
• (a) Muñoz W, Lamm A, Poppers D, Lamm S. Acetazolamide promotes decreased consumption of carbonated drinks and weight loss. Oxf Med Case Reports 2018;2018:omy081.
   PubMedGoogle Scholar
  (b) Bejaoui M, Pantazi E, De Luca V, et al. Acetazolamide protects steatotic liver grafts against cold ischemia reperfusion injury. J Pharmacol Exp Ther 2015;355:191–8. (c) Supuran CT. Carbonic anhydrase inhibitors as emerging drugs for the treatment of obesity. Expert Opin Emerg Drugs 2012;17:11–5. (d) Supuran CT, Di Fiore A, De Simone G. Carbonic anhydrase inhibitors as emerging drugs for the treatment of obesity. Expert Opin Emerg Drugs 2008;13:383–92.
   PubMed Web of Science ®Google Scholar
• (a) Costa G, Carta F, Ambrosio FA, et al. A computer-assisted discovery of novel potential anti-obesity compounds as selective carbonic anhydrase VA inhibitors. Eur J Med Chem 2019;181:111565.
   PubMed Web of Science ®Google Scholar
  (b) Costa G, Gidaro MC, Vullo D, et al. al. Active components of essential oils as anti-obesity potential drugs investigated by in silico techniques. J Agric Food Chem 2016;64:5295–300. (c) Arechederra RL, Waheed A, Sly WS, et al. al. Effect of sulfonamides as carbonic anhydrase VA and VB inhibitors on mitochondrial metabolic energy conversion. Bioorg Med Chem 2013;21:1544–8.
   PubMed Web of Science ®Google Scholar
• (a) Supuran CT. For the treatment of idiopathic intracranial hypertension. Expert Rev Neurother. 2015;15:851–856;
   PubMed Web of Science ®Google Scholar
  (b) Supuran CT. Drug interaction considerations in the therapeutic use of carbonic anhydrase inhibitors. Expert Opin Drug Metab Toxicol 2016;12:423–31.
   PubMed Web of Science ®Google Scholar
• a)Di Cesare Mannelli L, Micheli L, Carta F, et al. Carbonic anhydrase inhibition for the management of cerebral ischemia: in vivo evaluation of sulfonamide and coumarin inhibitors. Enzyme Inhib Med Chem 2016;31:894–9. (b) Angeli A, di Cesare Mannelli L, Trallori E, et al. Design, synthesis, and X-ray of selenides as new class of agents for prevention of diabetic cerebrovascular pathology. ACS Med Chem Lett 2018;9:462–7.
   PubMed Web of Science ®Google Scholar
• (a) Carta F, Di Cesare Mannelli L, Pinard M, et al. A class of sulfonamide carbonic anhydrase inhibitors with neuropathic pain modulating effects. Bioorg Med Chem 2015;23:1828–40.
   PubMed Web of Science ®Google Scholar
  (b) Vullo D, Voipio J, Innocenti A, et al. Carbonic anhydrase inhibitors. Inhibition of the human cytosolic isozyme VII with aromatic and heterocyclic sulfonamides. Bioorg Med Chem Lett 2005;15:971–6.
   PubMed Web of Science ®Google Scholar
• Supuran CT. Carbonic anhydrase inhibition and the management of neuropathic pain. Expert Rev Neurother 2016;16:961–8.
   PubMed Web of Science ®Google Scholar
• Margheri F, Ceruso M, Carta F, et al. Overexpression of the transmembrane carbonic anhydrase isoforms IX and XII in the inflamed synovium. J Enzyme Inhib Med Chem 2016;31:60–3.
   PubMed Web of Science ®Google Scholar
• (a) Bua S, Di Cesare Mannelli L, Vullo D, et al. Design and synthesis of novel nonsteroidal anti-inflammatory drugs and carbonic anhydrase inhibitors hybrids (NSAIDs-CAIs) for the treatment of rheumatoid arthritis. J Med Chem 2017;60:1159–70.
   PubMed Web of Science ®Google Scholar
  (b) Bua S, Lucarini L, Micheli L, et al. Bioisosteric development of multitarget nonsteroidal anti-inflammatory drug-carbonic anhydrases inhibitor hybrids for the management of rheumatoid arthritis. J Med Chem 2020;63:2325–42. (c) Akgul O, Di Cesare Mannelli L, Vullo D, et al. Discovery of novel nonsteroidal anti-inflammatory drugs and carbonic anhydrase inhibitors hybrids (NSAIDs-CAIs) for the management of rheumatoid arthritis. J Med Chem 2018;61:4961–77.
   PubMed Web of Science ®Google Scholar
• (a) Micheli L, Bozdag M, Akgul O, et al. Pain relieving effect of-NSAIDs-CAIs hybrid molecules: systemic and intra-articular treatments against rheumatoid arthritis. Int J Mol Sci 2019;20:1923.
   Web of Science ®Google Scholar
  (b) Lucarini L, Durante M, Sgambellone S, et al. Effects of new NSAID-CAI hybrid compounds in inflammation and lung fibrosis. Biomolecules 2020;10:1307.
   Web of Science ®Google Scholar
• Berrino E, Milazzo L, Micheli L, et al. Synthesis and evaluation of carbonic anhydrase inhibitors with carbon monoxide releasing properties for the management of rheumatoid arthritis. J Med Chem 2019;62:7233–49.
   PubMed Web of Science ®Google Scholar
• Pastorek J, Pastoreková S, Callebaut I, et al. Cloning and characterization of MN, a human tumor-associated protein with a domain homologous to carbonic anhydrase and a putative helix-loop-helix DNA binding segment. Oncogene 1994;9:2877–88.
   PubMed Web of Science ®Google Scholar
• Türeci O, Sahin U, Vollmar E, et al. Human carbonic anhydrase XII: cDNA cloning, expression, and chromosomal localization of a carbonic anhydrase gene that is overexpressed in some renal cell cancers. Proc Natl Acad Sci USA 1998;95:7608–13.
   PubMed Web of Science ®Google Scholar
• Svastová E, Hulíková A, Rafajová M, et al. Hypoxia activates the capacity of tumor-associated carbonic anhydrase IX to acidify extracellular pH. FEBS Lett 2004;577:439–45.
   PubMed Web of Science ®Google Scholar
• Cecchi A, Hulikova A, Pastorek J, et al. Carbonic anhydrase inhibitors. Design of fluorescent sulfonamides as probes of tumor-associated carbonic anhydrase IX that inhibit isozyme IX-mediated acidification of hypoxic tumors. J Med Chem 2005;48:4834–41.
   PubMed Web of Science ®Google Scholar
• Ahlskog JK, Dumelin CE, Trüssel S, et al. In vivo targeting of tumor-associated carbonic anhydrases using acetazolamide derivatives. Bioorg Med Chem Lett 2009;19:4851–6.
   PubMed Web of Science ®Google Scholar
• Buller F, Steiner M, Frey K, et al. Selection of carbonic anhydrase IX inhibitors from one million DNA-encoded compounds. ACS Chem Biol 2011;6:336–44.
   PubMed Web of Science ®Google Scholar
• Lou Y, McDonald PC, Oloumi A, et al. Targeting tumor hypoxia: suppression of breast tumor growth and metastasis by novel carbonic anhydrase IX inhibitors. Cancer Res 2011;71:3364–76.
   PubMed Web of Science ®Google Scholar
• Krall N, Pretto F, Decurtins W, et al. A small-molecule drug conjugate for the treatment of carbonic anhydrase IX expressing tumors. Angew Chem Int Ed Engl 2014;53:4231–5.
   PubMed Web of Science ®Google Scholar
• Ebbesen P, Pettersen EO, Gorr TA, et al. Taking advantage of tumor cell adaptations to hypoxia for developing new tumor markers and treatment strategies. J Enzyme Inhib Med Chem 2009;24: 1–39.
   PubMed Web of Science ®Google Scholar
• Pettersen EO, Ebbesen P, Gieling RG, et al. Targeting tumour hypoxia to prevent cancer metastasis. From biology, biosensing and technology to drug development: the METOXIA consortium. J Enzyme Inhib Med Chem 2015;30:689–721.
   PubMed Web of Science ®Google Scholar
• Supuran CT, Alterio V, Di Fiore A, et al. Inhibition of carbonic anhydrase IX targets primary tumors, metastases, and cancer stem cells: three for the price of one. Med Res Rev 2018;38:1799–836.
   PubMed Web of Science ®Google Scholar
• McDonald PC, Winum JY, Supuran CT, Dedhar S. Recent developments in targeting carbonic anhydrase IX for cancer therapeutics. Oncotarget 2012;3:84–97.
   PubMed Web of Science ®Google Scholar
• Angeli A, Carta F, Nocentini A, et al. Carbonic anhydrase inhibitors targeting metabolism and tumor microenvironment. Metabolites 2020;10:412.
   PubMed Web of Science ®Google Scholar
• Burianova V, Kalinin S, Supuran CT, Krasavin M. Radiotracers for positron emission tomography (PET) targeting tumour-associated carbonic anhydrase isoforms. Eur J Med Chem 2020;2021:113046.
   Google Scholar
• Andring JT, Fouch M, Akocak S, et al. Structural basis of nanomolar inhibition of tumor-associated carbonic anhydrase IX: X-ray crystallographic and inhibition study of lipophilic inhibitors with acetazolamide backbone. J Med Chem 2020;63:13064–75.
   PubMed Web of Science ®Google Scholar
• Alterio V, Hilvo M, Di Fiore A, et al. Crystal structure of the catalytic domain of the tumor-associated human carbonic anhydrase IX. Proc Natl Acad Sci USA 2009;106:16233–8.
   PubMed Web of Science ®Google Scholar
• Whittington DA, Waheed A, Ulmasov B, et al. Crystal structure of the dimeric extracellular domain of human carbonic anhydrase XII, a bitopic membrane protein overexpressed in certain cancer tumor cells. Proc Natl Acad Sci USA 2001;98:9545–50.
   PubMed Web of Science ®Google Scholar
• Di Fiore A, Truppo E, Supuran CT, et al. Crystal structure of the C183S/C217S mutant of human CA VII in complex with acetazolamide. Bioorg Med Chem Lett 2010;20:5023–6.
   PubMed Web of Science ®Google Scholar
• Di Fiore A, Monti SM, Hilvo M, et al. Crystal structure of human carbonic anhydrase XIII and its complex with the inhibitor acetazolamide. Proteins 2009;74:164–75.
   PubMed Web of Science ®Google Scholar
• Alterio V, Pan P, Parkkila S, et al. The structural comparison between membrane-associated human carbonic anhydrases provides insights into drug design of selective inhibitors. Biopolymers 2014;101:769–78.
   PubMed Web of Science ®Google Scholar
• Pilka ES, Kochan G, Oppermann U, Yue WW. Crystal structure of the secretory isozyme of mammalian carbonic anhydrases CA VI: implications for biological assembly and inhibitor development. Biochem Biophys Res Commun 2012;419:485–9.
   PubMed Web of Science ®Google Scholar
• Briganti F, Mangani S, Orioli P, et al. Carbonic anhydrase activators: X-ray crystallographic and spectroscopic investigations for the interaction of isozymes I and II with histamine. Biochemistry 1997;36:10384–92.
   PubMed Web of Science ®Google Scholar
• (a) Supuran CT. Carbonic anhydrase activators. Future Med Chem 2018;10:561–73.
   PubMed Web of Science ®Google Scholar
  (b) Supuran CT, Balaban AT. Carbonic anhydrase activators. Part 8. pKa–activation relationship in a series of amino acid derivatives activators of isozyme II. Rev Roum Chim 1994;39:107–13. (c) Duda D, Tu C, Qian M, et al. Structural and kinetic analysis of the chemical rescue of the proton transfer function of carbonic anhydrase II. Biochemistry 2001;40:1741–8.
   Web of Science ®Google Scholar
• Temperini C, Scozzafava A, Vullo D, Supuran CT. Carbonic anhydrase activators. Activation of isozymes I, II, IV, VA, VII, and XIV with l- and d-histidine and crystallographic analysis of their adducts with isoform II: engineering proton-transfer processes within the active site of an enzyme. Chemistry 2006;12:7057–66.
   PubMed Web of Science ®Google Scholar
• (a) Temperini C, Scozzafava A, Supuran CT. Carbonic anhydrase activation and the drug design. Curr Pharm Des 2008;14:708–15.
   PubMed Web of Science ®Google Scholar
  (b) Temperini C, Innocenti A, Scozzafava A, et al. Carbonic anhydrase activators: L-Adrenaline plugs the active site entrance of isozyme II, activating better isoforms I, IV, VA, VII, and XIV. Bioorg Med Chem Lett 2007;17:628–35.
   PubMed Web of Science ®Google Scholar
• (a) Temperini C, Scozzafava A, Vullo D, et al. Carbonic anhydrase activators. Activation of isoforms I, II, IV, VA, VII, and XIV with L- and D-phenylalanine and crystallographic analysis of their adducts with isozyme II: stereospecific recognition within the active site of an enzyme and its consequences for the drug design. J Med Chem 2006;49:3019–27.
   PubMed Web of Science ®Google Scholar
  (b) Temperini C, Innocenti A, Scozzafava A, et al. Carbonic anhydrase activators: kinetic and x-ray crystallographic study for the interaction of D- and L-tryptophan with the mammalian isoforms I-XIV. Bioorg Med Chem 2008;16:8373–837.
   PubMed Web of Science ®Google Scholar
• (a) Dave K, Ilies MA, Scozzafava A, et al. An inhibitor-like binding mode of a carbonic anhydrase activator within the active site of isoform II. Bioorg Med Chem Lett 2011;21:2764–8.
   PubMed Web of Science ®Google Scholar
  (b) Bhatt A, Mondal UK, Supuran CT, et al. crystal structure of carbonic anhydrase II in complex with an activating ligand: implications in neuronal function. Mol Neurobiol 2018;55:7431–7.
   PubMed Web of Science ®Google Scholar
• (a) Vullo D, Innocenti A, Nishimori I, et al. Carbonic anhydrase activators: activation of the human isoforms VII (cytosolic) and XIV (transmembrane) with amino acids and amines. Bioorg Med Chem Lett 2007;17:4107–12.
   PubMed Web of Science ®Google Scholar
  (b) Pastorekova S, Vullo D, Nishimori I, et al. Carbonic anhydrase activators: activation of the human tumor-associated isozymes IX and XII with amino acids and amines. Bioorg Med Chem 2008;16:3530–6.
   PubMed Web of Science ®Google Scholar
• Vullo D, Nishimori I, Innocenti A, et al. Carbonic anhydrase activators: an activation study of the human mitochondrial isoforms VA and VB with amino acids and amines. Bioorg Med Chem Lett 2007;17:1336–40.
   PubMed Web of Science ®Google Scholar
• a). Saada MC, Vullo D, Montero JL, et al. Carbonic anhydrase I and II activation with mono- and dihalogenated histamine derivatives. Bioorg Med Chem Lett 2011;21:4884–7. (b) Saada MC, Vullo D, Montero JL, et al. Mono- and di-halogenated histamine, histidine and carnosine derivatives are potent carbonic anhydrase I, II, VII, XII and XIV activators. Bioorg Med Chem 2014;22:4752–8. (c) Vistoli G, Aldini G, Fumagalli L, et al. Activation effects of carnosine- and histidine-containing dipeptides on human carbonic anhydrases: a comprehensive study. Int J Mol Sci 2020;21:1761.
   PubMed Web of Science ®Google Scholar
• (a) Supuran CT, Dinculescu A, Balaban AT. Carbonic anhydrase activators. Part 5. CA II activation by 2,4,6-trisubstituted pyridinium cations with 1-(ω-aminoalkyl) side chains. Rev Roum Chim 1993;38:343–9.
   Web of Science ®Google Scholar
  (b) Draghici B, Vullo D, Akocak S, et al. Ethylene bis-imidazoles are highly potent and selective activators for isozymes VA and VII of carbonic anhydrase, with a potential nootropic effect. Chem Commun (Camb) 2014;50:5980–3.
   PubMed Web of Science ®Google Scholar
• (a) Akocak S, Lolak N, Bua S, et al. Activation of human α-carbonic anhydrase isoforms I, II, IV and VII with bis-histamine schiff bases and bis-spinaceamine substituted derivatives. J Enzyme Inhib Med Chem 2019;34:1193–8.
   PubMed Web of Science ®Google Scholar
  (b) Akocak S, Lolak N, Bua S, et al. α-Carbonic anhydrases are strongly activated by spinaceamine derivatives. Bioorg Med Chem 2019;27:800–4.
   PubMed Web of Science ®Google Scholar
• a). Chiaramonte N, Maach S, Biliotti C, et al. Synthesis and carbonic anhydrase activating properties of a series of 2-amino-imidazolines structurally related to clonidine. J Enzyme Inhib Med Chem 2020;35:1003–10. (b) Angeli A, Vaiano F, Mari F, et al. Psychoactive substances belonging to the amphetamine class potently activate brain carbonic anhydrase isoforms VA, VB, VII, and XII. J Enzyme Inhib Med Chem 2017;32:1253–9.
   PubMed Web of Science ®Google Scholar
• (a) Zhang Y, Supuran CT, Barboiu M. Exponential activation of carbonic anhydrase by encapsulation in dynameric host matrices with chiral discrimination. Chemistry 2018;24:715–20.
   PubMed Web of Science ®Google Scholar
  (b) Le Duc Y, Licsandru E, Vullo D, et al. Carbonic anhydrases activation with 3-amino-1H-1,2,4-triazole-1-carboxamides: discovery of subnanomolar isoform II activators. Bioorg Med Chem 2017;25:1681–6. (c) Licsandru E, Tanc M, Kocsis I, et al. A class of carbonic anhydrase I - selective activators. J Enzyme Inhib Med Chem 2017;32:37–46. (d) Zhang Y, Legrand YM, Petit E, et al. Dynamic encapsulation and activation of carbonic anhydrase in multivalent dynameric host matrices. Chem Commun (Camb) 2016;52:4053–5. (e) Abdelrahim MY, Tanc M, Winum JY, et al. Dominant behaviours in the expression of human carbonic anhydrase hCA I activity. Chem Commun (Camb) 2014;50:8043–6.
   PubMed Web of Science ®Google Scholar
• Canto de Souza L, Provensi G, Vullo D, et al. Carbonic anhydrase activation enhances object recognition memory in mice through phosphorylation of the extracellular signal-regulated kinase in the cortex and the hippocampus. Neuropharmacology 2017;118:148–56.
   PubMed Web of Science ®Google Scholar
• Blandina P, Provensi G, Passsani MB, et al. Carbonic anhydrase modulation of emotional memory. Implications for the treatment of cognitive disorders. J Enzyme Inhib Med Chem 2020;35:1206–14.
   PubMed Web of Science ®Google Scholar
• Schmidt SD, Costa A, Rani B, et al. The role of carbonic anhydrases in extinction of contextual fear memory. Proc Natl Acad Sci USA 2020;117:16000–8.
   PubMed Web of Science ®Google Scholar
• Jonsson BH, Liljas A. Perspectives on the classical enzyme carbonic anhydrase and the search for inhibitors. Biophys J 2020;119:1275–80.
   PubMed Web of Science ®Google Scholar
• Angeli A, Carta F, Nocentini A, et al. Response to perspectives on the classical enzyme carbonic anhydrase and the search for inhibitors. Biophys J 2021;120:178–81.
   PubMed Web of Science ®Google Scholar
• Supuran CT. Experimental carbonic anhydrase inhibitors for the treatment of hypoxic tumors. J Exp Pharmacol 2020;12:603–17.
   PubMedGoogle Scholar
• Jonsson BH, Liljas A. Comments to the editor due to the response by the supuran group to our article. Biophys J 2021;120:182–3.
   PubMed Web of Science ®Google Scholar
• Maryanoff BE, Nortey SO, Gardocki JF, et al. Anticonvulsant O-alkyl sulfamates. 2,3:4,5-Bis-O-(1-methylethylidene)-beta-D-fructopyranose sulfamate and related compounds. J Med Chem 1987;30:880–7.
   PubMed Web of Science ®Google Scholar
• Dodgson SJ, Shank RP, Maryanoff BE. Topiramate as an inhibitor of carbonic anhydrase isoenzymes. Epilepsia 2000;41:35–9.
   PubMed Web of Science ®Google Scholar
• Klinger AL, McComsey DF, Smith-Swintosky V, et al. Inhibition of carbonic anhydrase-II by sulfamate and sulfamide groups: an investigation involving direct thermodynamic binding measurements. J Med Chem 2006;49:3496–500.
   PubMed Web of Science ®Google Scholar
• Shank RP, Smith-Swintosky VL, Maryanoff BE. Carbonic anhydrase inhibition. Insight into the characteristics of zonisamide, topiramate, and the sulfamide cognate of topiramate. J Enzyme Inhib Med Chem 2008;23:271–6.
   PubMed Web of Science ®Google Scholar
• Casini A, Antel J, Abbate F, et al. Carbonic anhydrase inhibitors: SAR and X-ray crystallographic study for the interaction of sugar sulfamates/sulfamides with isozymes I, II and IV. Bioorg Med Chem Lett 2003;13:841–5.
   PubMed Web of Science ®Google Scholar
• Nguyen GTH, Tran TN, Podgorski MN, et al. Nanoscale ion emitters in native mass spectrometry for measuring ligand-protein binding affinities. ACS Cent Sci 2019;5:308–18.
   PubMed Web of Science ®Google Scholar
• (a) Nguyen GTH, Nocentini A, Angeli A, et al. Perfluoroalkyl substances of significant environmental concern can strongly inhibit human carbonic anhydrase isozymes. Anal Chem 2020;92:4614–22.
   PubMed Web of Science ®Google Scholar
  (b) Nguyen GTH, Leung WY, Tran TN, et al. Mechanism for the binding of netropsin to hairpin DNA revealed using nanoscale ion emitters in native mass spectrometry. Anal Chem 2020;92:1130–7.
   PubMed Web of Science ®Google Scholar
• Matulis D. Structural details of the enzymatic catalysis of carbonic anhydrase II via a mutation of valine to isoleucine. IUCrJ 2020;7:953–4.
   PubMed Web of Science ®Google Scholar
• Matulis D, Kranz JK, Salemme FR, Todd MJ. Thermodynamic stability of carbonic anhydrase: measurements of binding affinity and stoichiometry using ThermoFluor. Biochemistry 2005;44:5258–66.
   PubMed Web of Science ®Google Scholar
• Linkuvienė V, Krainer G, Chen WY, Matulis D. Isothermal titration calorimetry for drug design: precision of the enthalpy and binding constant measurements and comparison of the instruments. Anal Biochem 2016;515:61–4.
   PubMed Web of Science ®Google Scholar
• (a) Vullo D, Ruusuvuori E, Kaila K, et al. Carbonic anhydrase inhibitors: inhibition of the cytosolic human isozyme VII with anions. Bioorg Med Chem Lett 2006;16:3139–43.
   PubMed Web of Science ®Google Scholar
  (b) Vullo D, Franchi M, Gallori E, et al. Carbonic anhydrase inhibitors. inhibition of cytosolic isozymes I and II and transmembrane, cancer-associated isozyme IX with anions. J Enzyme Inhib Med Chem 2003;18:403–6. (c) Innocenti A, Vullo D, Pastorek J, et al. Carbonic anhydrase inhibitors. Inhibition of transmembrane isozymes XII (cancer-associated) and XIV with anions. Bioorg Med Chem Lett 2007;17:1532–7. (d) Innocenti A, Lehtonen JM, Parkkila S, et al. Carbonic anhydrase inhibitors. Inhibition of the newly isolated murine isozyme XIII with anions. Bioorg Med Chem Lett 2004;14:5435–9.
   PubMed Web of Science ®Google Scholar
• (a) Sūdžius J, Baranauskienė L, Golovenko D, et al. 4-[N-(substituted 4-pyrimidinyl)amino]benzenesulfonamides as inhibitors of carbonic anhydrase isozymes I, II, VII, and XIII. Bioorg Med Chem 2010;18:7413–21.
   PubMed Web of Science ®Google Scholar
  (b) Čapkauskaitė E, Zubrienė A, Baranauskienė L, et al. Design of [(2-pyrimidinylthio)acetyl]benzenesulfonamides as inhibitors of human carbonic anhydrases. Eur J Med Chem 2012;51:259–70.
   PubMed Web of Science ®Google Scholar
• Zubrienė A, Čapkauskaitė E, Gylytė J, et al. Benzenesulfonamides with benzimidazole moieties as inhibitors of carbonic anhydrases I, II, VII, XII and XIII. J Enzyme Inhib Med Chem 2014;29:124–31.
   PubMed Web of Science ®Google Scholar
• Dudutienė V, Matulienė J, Smirnov A, et al. Discovery and characterization of novel selective inhibitors of carbonic anhydrase IX. J Med Chem 2014;57:9435–46.
   PubMed Web of Science ®Google Scholar
• Dudutienė V, Zubrienė A, Smirnov A, et al. Functionalization of fluorinated benzenesulfonamides and their inhibitory properties toward carbonic anhydrases. ChemMedChem 2015;10:662–87.
   PubMed Web of Science ®Google Scholar
• Zakšauskas A, Čapkauskaitė E, Jezepčikas L, et al. Design of two-tail compounds with rotationally fixed benzenesulfonamide ring as inhibitors of carbonic anhydrases. Eur J Med Chem 2018;156:61–78.
   PubMed Web of Science ®Google Scholar
• Zakšauskas A, Čapkauskaitė E, Jezepčikas L, et al. Halogenated and di-substituted benzenesulfonamides as selective inhibitors of carbonic anhydrase isoforms. Eur J Med Chem 2020;185:111825.
   PubMed Web of Science ®Google Scholar
• Khalifah RG. The carbon dioxide hydration activity of carbonic anhydrase. J Bio. Chem 1971;246:2561–73.
   PubMed Web of Science ®Google Scholar
• Paketurytė V, Zubrienė A, Ladbury JE, Matulis D. Intrinsic thermodynamics of protein-ligand binding by isothermal titration calorimetry as aid to drug design. Methods Mol Biol. 2019;1964:61–74.
   PubMedGoogle Scholar
• Kišonaitė M, Zubrienė A, Capkauskaitė E, et al. Intrinsic thermodynamics and structure correlation of benzenesulfonamides with a pyrimidine moiety binding to carbonic anhydrases I, II, VII, XII, and XIII. PLoS One 2014;9:e114106.
   PubMed Web of Science ®Google Scholar
• (a) Khalifah RG, Zhang F, Parr JS, Rowe ES. Thermodynamics of binding of the CO2-competitive inhibitor imidazole and related compounds to human carbonic anhydrase I: an isothermal titration calorimetry approach to studying weak binding by displacement with strong inhibitors. Biochemistry 1993;32:3058–66.
   PubMed Web of Science ®Google Scholar
  (b) An H, Tu C, Duda D, et al. Chemical rescue in catalysis by human carbonic anhydrases II and III. Biochemistry 2002;41:3235–42.
   PubMed Web of Science ®Google Scholar
• Gaspari R, Rechlin C, Heine A, et al. Kinetic and structural insights into the mechanism of binding of sulfonamides to human carbonic anhydrase by computational and experimental studies. J Med Chem 2016;59:4245–56.
   PubMed Web of Science ®Google Scholar
• De Simone G, Alterio V, Supuran CT. Exploiting the hydrophobic and hydrophilic binding sites for designing carbonic anhydrase inhibitors. Expert Opin Drug Discov 2013;8:793–810.
   PubMed Web of Science ®Google Scholar
• Glöckner S, Ngo K, Sager CP, et al. Conformational changes in alkyl chains determine the thermodynamic and kinetic binding profiles of carbonic anhydrase inhibitors. ACS Chem Biol 2020;15:675–85.
   PubMed Web of Science ®Google Scholar
• Glöckner S, Ngo K, Wagner B, et al. The influence of varying fluorination patterns on the thermodynamics and kinetics of benzenesulfonamide binding to human carbonic anhydrase II. Biomolecules 2020;10:509.
   Web of Science ®Google Scholar
• Snyder PW, Mecinovic J, Moustakas DT, et al. Mechanism of the hydrophobic effect in the biomolecular recognition of arylsulfonamides by carbonic anhydrase. Proc Natl Acad Sci USA 2011;108:17889–94.
   PubMed Web of Science ®Google Scholar
• Fox JM, Kang K, Sastry M, et al. Water-restructuring mutations can reverse the thermodynamic signature of ligand binding to human carbonic anhydrase. Angew Chem Int Ed Engl 2017;56:3833–7.
   PubMed Web of Science ®Google Scholar
• Breiten B, Lockett MR, Sherman W, et al. Water networks contribute to enthalpy/entropy compensation in protein-ligand binding. J Am Chem Soc 2013;135:15579–84.
   PubMed Web of Science ®Google Scholar
• Fox JM, Kang K, Sherman W, et al. Interactions between Hofmeister anions and the binding pocket of a protein. J Am Chem Soc 2015;137:3859–66.
   PubMed Web of Science ®Google Scholar
• Talibov VO, Linkuvienė V, Matulis D, Danielson UH. Kinetically selective inhibitors of human carbonic anhydrase isozymes I, II, VII, IX, XII, and XIII. J Med Chem 2016;59:2083–93.
   PubMed Web of Science ®Google Scholar
• Maren TH. Direct measurements of the rate constants of sulfonamides with carbonic anhydrase. Mol Pharmacol 1992;41:419–26.
   PubMed Web of Science ®Google Scholar
• (a) Maren TH, Clare BW, Supuran CT. Structure-activity studies of sulfonamide carbonic anhydrase inhibitors. Roum Chem Quart Rev 1994;2:259–82.
   Google Scholar
  (b) Maren TH, Conroy CW. A new class of carbonic anhydrase inhibitor. J Biol Chem 1993;268:26233–9.
   PubMed Web of Science ®Google Scholar
• Köhler K, Hillebrecht A, Schulze Wischeler J, et al. Saccharin inhibits carbonic anhydrases: possible explanation for its unpleasant metallic aftertaste. Angew Chem Int Ed Engl 2007;46:7697–9.
   PubMed Web of Science ®Google Scholar
• McDonald PC, Chia S, Bedard PL, et al. A phase 1 study of SLC-0111, a novel inhibitor of carbonic anhydrase IX, in patients with advanced solid tumors. Am J Clin Oncol 2020;43:484–90.
   PubMed Web of Science ®Google Scholar
• Lock FE, McDonald PC, Lou Y, et al. Targeting carbonic anhydrase IX depletes breast cancer stem cells within the hypoxic niche. Oncogene 2013;32:5210–9.
   PubMed Web of Science ®Google Scholar
• Kreuzer M, Banerjee A, Birts CN, et al. Glycolysis, via NADH-dependent dimerisation of CtBPs, regulates hypoxia-induced expression of CAIX and stem-like breast cancer cell survival. FEBS Lett 2020;594:2988–3001.
   PubMed Web of Science ®Google Scholar
• Gibadulinova A, Bullova P, Strnad H, et al. CAIX-mediated control of LIN28/let-7 axis contributes to metabolic adaptation of breast cancer cells to hypoxia. Int J Mol Sci 2020;21:4299.
   Web of Science ®Google Scholar
• Swayampakula M, McDonald PC, Vallejo M, et al. The interactome of metabolic enzyme carbonic anhydrase IX reveals novel roles in tumor cell migration and invadopodia/MMP14-mediated invasion. Oncogene 2017;36:6244–61.
   PubMed Web of Science ®Google Scholar
• Lee SH, Griffiths JR. How and why are cancers acidic? Carbonic anhydrase IX and the homeostatic control of tumour extracellular pH. Cancers (Basel) 2020;12:1616.
   PubMed Web of Science ®Google Scholar
• Ciccone V, Filippelli A, Angeli A, et al. Pharmacological inhibition of CA-IX impairs tumor cell proliferation, migration and invasiveness. Int J Mol Sci 2020;21:2983.
   Web of Science ®Google Scholar
• Pastorekova S, Gillies RJ. The role of carbonic anhydrase IX in cancer development: links to hypoxia, acidosis, and beyond. Cancer Metastasis Rev 2019;38:65–77.
   PubMed Web of Science ®Google Scholar
• Lee SH, McIntyre D, Honess D, et al. Carbonic anhydrase IX is a pH-stat that sets an acidic tumour extracellular pH in vivo. Br J Cancer 2018;119:622–30.
   PubMed Web of Science ®Google Scholar
• McDonald PC, Chafe SC, Brown WS, et al. Regulation of pH by carbonic anhydrase 9 mediates survival of pancreatic cancer cells with activated KRAS in response to hypoxia. Gastroenterology 2019;157:823–37.
   PubMed Web of Science ®Google Scholar
• Persi E, Duran-Frigola M, Damaghi M, et al. Systems analysis of intracellular pH vulnerabilities for cancer therapy. Nat Commun 2018;9:2997.
   PubMed Web of Science ®Google Scholar
• Boyd NH, Walker K, Fried J, et al. Addition of carbonic anhydrase 9 inhibitor SLC-0111 to temozolomide treatment delays glioblastoma growth in vivo. JCI Insight 2017;2:92928.
   PubMed Web of Science ®Google Scholar
• Iessi E, Logozzi M, Mizzoni D, et al. Rethinking the combination of proton exchanger inhibitors in cancer therapy. Metabolites 2017;8:2.
   PubMed Web of Science ®Google Scholar
• McDonald PC, Swayampakula M, Dedhar S. Coordinated regulation of metabolic transporters and migration/invasion by carbonic anhydrase IX. Metabolites 2018;8:20.
   PubMed Web of Science ®Google Scholar
• Chafe SC, McDonald PC, Saberi S, et al. Targeting hypoxia-induced carbonic anhydrase IX enhances immune-checkpoint blockade locally and systemically. Cancer Immunol Res 2019;7:1064–78.
   PubMed Web of Science ®Google Scholar
• Damgaci S, Ibrahim-Hashim A, Enriquez-Navas PM, et al. Hypoxia and acidosis: immune suppressors and therapeutic targets. Immunology 2018;154:354–62.
   PubMed Web of Science ®Google Scholar
• Kuchuk O, Tuccitto A, Citterio D, et al. pH regulators to target the tumor immune microenvironment in human hepatocellular carcinoma. Oncoimmunology 2018;7:e1445452.
   PubMed Web of Science ®Google Scholar
• Ward C, Meehan J, Gray M, et al. Carbonic anhydrase IX (CAIX), cancer, and radiation responsiveness. Metabolites 2018;8:13.
   PubMed Web of Science ®Google Scholar
• Doyen J, Parks SK, Marcié S, et al. Knock-down of hypoxia-induced carbonic anhydrases IX and XII radiosensitizes tumor cells by increasing intracellular acidosis. Front Oncol 2012;2:199.
   PubMedGoogle Scholar
• Serbian I, Schwarzenberger P, Loesche A, et al. Ureidobenzenesulfonamides as efficient inhibitors of carbonic anhydrase II. Bioorg Chem 2019;91:103123.
   PubMed Web of Science ®Google Scholar
• Vanchanagiri K, Emmerich D, Bruschke M, et al. Synthesis and biological investigation of new carbonic anhydrase IX (CAIX) inhibitors. Chem Biol Interact 2018;284:12–23.
   PubMed Web of Science ®Google Scholar
• Federici C, Lugini L, Marino ML, et al. Lansoprazole and carbonic anhydrase IX inhibitors sinergize against human melanoma cells. J Enzyme Inhib Med Chem 2016;31:119–25.
   PubMed Web of Science ®Google Scholar
• Andreucci E, Peppicelli S, Carta F, et al. Carbonic anhydrase IX inhibition affects viability of cancer cells adapted to extracellular acidosis. J Mol Med (Berl) 2017;95:1341–53.
   PubMed Web of Science ®Google Scholar
• Bryant JL, Gieling RG, Meredith SL, et al. Novel carbonic anhydrase IX-targeted therapy enhances the anti-tumour effects of cisplatin in small cell lung cancer. Int J Cancer 2018;142:191–201.
   PubMed Web of Science ®Google Scholar
• Logsdon DP, Grimard M, Luo M, et al. Regulation of HIF1α under hypoxia by APE1/Ref-1 impacts CA9 expression: dual targeting in patient-derived 3D pancreatic cancer models. Mol Cancer Ther 2016;15:2722–32.
   PubMed Web of Science ®Google Scholar
• Peppicelli S, Andreucci E, Ruzzolini J, et al. The Carbonic Anhydrase IX inhibitor SLC-0111 as emerging agent against the mesenchymal stem cell-derived pro-survival effects on melanoma cells. J Enzyme Inhib Med Chem 2020;35:1185–93.
   PubMed Web of Science ®Google Scholar
• Genah S, Angeli A, Supuran CT, Morbidelli L. Effect of carbonic anhydrase IX inhibitors on human endothelial cell survival. Pharmacol Res 2020;159:104964.
   PubMed Web of Science ®Google Scholar
• Riemann A, Güttler A, Haupt V, et al. Inhibition of carbonic anhydrase IX by ureidosulfonamide inhibitor U104 reduces prostate cancer cell growth, but does not modulate daunorubicin or cisplatin cytotoxicity. Oncol Res 2018;26:191–200.
   PubMed Web of Science ®Google Scholar
• Güttler A, Theuerkorn K, Riemann A, et al. Cellular and radiobiological effects of carbonic anhydrase IX in human breast cancer cells. Oncol Rep 2019;41:2585–94.
   PubMed Web of Science ®Google Scholar
• Lee JY, Alexeyev M, Kozhukhar N, et al. Carbonic anhydrase IX is a critical determinant of pulmonary microvascular endothelial cell pH regulation and angiogenesis during acidosis. Am J Physiol Lung Cell Mol Physiol 2018;315:L41–L51.
   PubMed Web of Science ®Google Scholar
• Lee JY, Onanyan M, Garrison I, et al. Extrinsic acidosis suppresses glycolysis and migration while increasing network formation in pulmonary microvascular endothelial cells. Am J Physiol Lung Cell Mol Physiol 2019;317:L188–L201.
   PubMed Web of Science ®Google Scholar
• Bernardino RL, Dias TR, Moreira BP, et al. Carbonic anhydrases are involved in mitochondrial biogenesis and control the production of lactate by human Sertoli cells. Febs J 2019;286:1393–406.
   PubMed Web of Science ®Google Scholar
• Petrenko M, Güttler A, Funtan A, et al. Combined 3-O-acetylbetulin treatment and carbonic anhydrase IX inhibition results in additive effects on human breast cancer cells. Chem Biol Interact 2021;333:109326.
   PubMed Web of Science ®Google Scholar
• Venkateswaran G, Dedhar S. Interplay of carbonic anhydrase IX with amino acid and acid/base transporters in the hypoxic tumor microenvironment. Front Cell Dev Biol 2020;8:602668.
   PubMed Web of Science ®Google Scholar
• Brown WS, McDonald PC, Nemirovsky O, et al. Overcoming adaptive resistance to KRAS and MEK inhibitors by co-targeting mTORC1/2 complexes in pancreatic cancer. Cell Rep Med 2020;1:100131.
   PubMedGoogle Scholar